About: Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.04 (-2.86%)
JAGX NASDAQ Jaguar Animal Health Inc
Jaguar Animal Health Inc share price
Atividade de preço de JAGX
Último preço
$ 2,040
Variação (24h)
-0,06 USD (2,86%)
Volume
168.55K
Volume (média 4 sem.)
-
Abertura
$ 2,08
Variação do dia
$ 2,00 - $ 2,09
Fechamento anterior
$ 2,10
Último negócio
29 Oct, 4:19 pm GMT+0
Atrasado
29 Oct, 4:19 pm GMT+0
JAGX price performance
Atrasado
29 Oct, 4:19 pm GMT+0
quote.marketSignals